- Home
- ATHA vs AIMD Comparison
ATHA vs AIMD Comparison
Compare ATHA & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- AIMD
- Stock Information
- Founded
- ATHA 2011
- AIMD 1984
- Country
- ATHA United States
- AIMD United States
- Employees
- ATHA N/A
- AIMD N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- AIMD Health Care
- Exchange
- ATHA Nasdaq
- AIMD Nasdaq
- Market Cap
- ATHA 10.6M
- AIMD 11.9M
- IPO Year
- ATHA 2020
- AIMD N/A
- Fundamental
- Price
- ATHA $0.42
- AIMD $2.94
- Analyst Decision
- ATHA Buy
- AIMD
- Analyst Count
- ATHA 4
- AIMD 0
- Target Price
- ATHA $11.25
- AIMD N/A
- AVG Volume (30 Days)
- ATHA 239.8K
- AIMD 72.7K
- Earning Date
- ATHA 07-31-2025
- AIMD 08-04-2025
- Dividend Yield
- ATHA N/A
- AIMD N/A
- EPS Growth
- ATHA N/A
- AIMD N/A
- EPS
- ATHA N/A
- AIMD N/A
- Revenue
- ATHA N/A
- AIMD $106,207.00
- Revenue This Year
- ATHA N/A
- AIMD N/A
- Revenue Next Year
- ATHA N/A
- AIMD N/A
- P/E Ratio
- ATHA N/A
- AIMD N/A
- Revenue Growth
- ATHA N/A
- AIMD 13.38
- 52 Week Low
- ATHA $0.22
- AIMD $2.00
- 52 Week High
- ATHA $3.67
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- ATHA 73.73
- AIMD 50.61
- Support Level
- ATHA $0.29
- AIMD $3.07
- Resistance Level
- ATHA $0.32
- AIMD $3.34
- Average True Range (ATR)
- ATHA 0.03
- AIMD 0.24
- MACD
- ATHA 0.01
- AIMD 0.04
- Stochastic Oscillator
- ATHA 78.16
- AIMD 60.37
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.